☆ 4.6 Meeting Abstract

Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn's disease

JOURNAL OF CROHNS & COLITIS (2019)

Journal

JOURNAL OF CROHNS & COLITIS

Volume 13, Issue -, Pages S438-S439

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/ecco-jcc/jjy222.765

Keywords

-

Categories

Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Dermatology

Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris

Merav Koschitzky, Kristina Navrazhina, Michael S. Garshick, Juana Gonzalez, Joseph Han, Sandra Garcet, James G. Krueger

Summary: This study aimed to identify biomarkers of cardiovascular (CV) risk in psoriasis blood that are reduced by ustekinumab. The results showed that 43 out of 276 proteins were down-regulated after treatment, and 8 of them were initially elevated above thresholds associated with enhanced CV risk.

EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction

Elisa Proietti, Renske W. M. Pauwels, Christien J. van der Woude, Michael Doukas, Lindsey Oudijk, Maikel P. Peppelenbosch, Ursula Grohmann, Marie-Rose B. S. Crombag, Annemarie C. de Vries, Gwenny M. Fuhler

Summary: This study is the first to demonstrate a correlation between serum and tissue UST levels. The tissue IL-23-to-UST ratio correlated with mucosal inflammation, and UST serum levels were more indicative of biochemical response.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Article Gastroenterology & Hepatology

Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary

Lorant Gonczi, Kata Szanto, Klaudia Farkas, Tamas Molnar, Tamas Szamosi, Eszter Schafer, Petra A. Golovics, Laszlo Barkai, Livia Lontai, Barbara Lovasz, Mark Juhasz, Arpad Patai, Krisztina Sarang, Aron Vincze, Patricia Sarlos, Alexandra Farkas, Zsolt Dubravcsik, Tamas G. Toth, Pal Miheller, Akos Ilias, Peter L. Lakatos

Summary: The clinical efficacy, drug sustainability, dose intensification, and therapeutic drug monitoring of ustekinumab therapy in patients with Crohn's disease were evaluated in this prospective, nationwide, multicenter cohort study. The study found that ustekinumab showed favorable drug sustainability and clinical efficacy in patients with severe disease phenotype and previous anti-tumor necrosis factor failure. However, frequent dose intensification was required.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Article Medicine, General & Internal

Association of Serum Immunoglobulins Levels With Specific Disease Phenotypes of Crohn's Disease: A Multicenter Analysis in China

Dong Juan Song, Jun Shen, Min Hu Chen, Zhan Ju Liu, Qian Cao, Pin Jin Hu, Xiang Gao, Jia Ming Qian, Kai Chun Wu, Li Jie Lai, Zhi Hua Ran

Summary: This study aimed to explore the associations between serum immunoglobulins levels and different disease phenotypes in Crohn's disease (CD) patients. Results indicated that certain serum immunoglobulins were linked to specific disease phenotypes of CD, suggesting further investigations are warranted to account for these associations.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II

Marco Vincenzo Lenti, Vivien Dolby, Tanya Clark, Veronica Hall, Suzanne Tattersall, Francesca Fairhurst, Catherine Kenneth, Rachael Walker, Karen Kemp, Simon Borg-Bartolo, Jimmy K. Limdi, Jo Taylor, Tristan Townsend, Sree Subramanian, Daniel Storey, Arash Assadsangabi, Catherine Stansfield, Paul Smith, Debra Byrne, Annalisa De Silvestri, Christian P. Selinger

Summary: The study showed that ustekinumab was more effective than vedolizumab at 14 weeks in CD patients, but there was no significant difference between the two at 52 weeks. Ustekinumab was found to be effective and well tolerated in this real-world cohort.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Environmental Sciences

Association of increased risk of cardiovascular diseases with higher levels of perfluoroalkylated substances in the serum of adults

Xinghui Feng, Guangfeng Long, Guowei Zeng, Qi Zhang, Binqian Song, Kai-Hong Wu

Summary: This study investigates the relationships between serum perfluoroalkylated substance (PFAS) levels and cardiovascular disease (CVD) risk. The results indicate a positive association between higher serum PFAS concentrations and an increased risk of CVD, mainly in males.

ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH (2022)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease

Jacob E. Ollech, Inessa Normatov, Noam Peleg, Jingzhou Wang, Shivani A. Patel, Victoria Rai, Yangtian Yi, Jorie Singer, Sushila R. Dalal, Atsushi Sakuraba, Russell D. Cohen, David T. Rubin, Joel Pekow

Summary: Shortening the ustekinumab dose interval to 4 weeks improved clinical and biological indices of disease activity in patients with Crohn's disease who did not respond to the standard dose every 8 weeks. This approach could be effective and safe for patients who lose response to the standard dose of ustekinumab.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor

Laurene Parrot, Catherine Dong, Franck Carbonnel, Antoine Meyer

Summary: In patients with Crohn's disease refractory to anti-TNF therapy, ustekinumab and vedolizumab show similar efficacy in induction, but ustekinumab appears to be more effective as maintenance treatment than vedolizumab.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers

Ciaran McDonald, Hilary Kerr, Eimear Gibbons, Tincymol Lukose, Danny Cheriyan, Gavin Harewood, Stephen Patchett, Aoibhlinn O'Toole, Orlaith Kelly, Karen Boland

Summary: This study found that maintenance ustekinumab serum trough levels higher than 2.3 μg/mL were associated with a higher success rate of achieving mucosal healing and mucosal response in patients with Crohn's disease. The aim of this study was to investigate the relationship between maintenance ustekinumab serum trough levels and mucosal healing and/or response in patients with Crohn's disease.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Article Gastroenterology & Hepatology

Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease

Michael D. Kappelman, Sruthi Adimadhyam, Laura Hou, Audrey E. Wolfe, Samantha Smith, Andrew L. Simon, Erick Moyneur, Juliane S. Reynolds, Sengwee Toh, Angela Dobes, Lauren E. Parlett, Kevin Haynes, Mano Selvan, Qianli Ma, Vinit Nair, Jessica Burris, Jennifer E. Dorand, Ghadeer K. Dawwas, James D. Lewis, Millie D. Long

Summary: This study compared the effectiveness and safety of ustekinumab and vedolizumab in a large US population of Crohn's disease patients who had lost response or become intolerant to anti-TNF therapy. The findings showed no difference in treatment persistence between the two drugs, but ustekinumab was associated with lower rates of all-cause hospitalization, nonsurgical CD hospitalization, and hospitalization for infection.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors

Sara Onali, Daniela Pugliese, Flavio Andrea Caprioli, Ambrogio Orlando, Livia Biancone, Olga Maria Nardone, Nicola Imperatore, Gionata Fiorino, Maria Cappello, Anna Viola, Maria Beatrice Principi, Cristina Bezzio, Annalisa Aratari, Sonia Carparelli, Silvia Mazzuoli, Francesco Manguso, Laurino Grossi, Giorgia Bodini, Davide Ribaldone, Giammarco Mocci, Agnese Miranda, Luigi Minerba, Agnese Favale, Mauro Grova, Ludovica Scucchi, Simone Segato, Walter Fries, Fabiana Castiglione, Alessandro Armuzzi, Massimo C. Fantini

Summary: In patients with CD where TNFi failed, both ustekinumab and vedolizumab showed similar clinical effectiveness after 26 weeks of treatment. At 1 year, vedolizumab was associated with a higher rate of clinical remission compared with ustekinumab. However, there was no significant difference between the two groups in objective outcomes at this time point.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Serum Ustekinumab Concentrations Are Associated With Improved Outcomes With the Magnetic Resonance Index of Activity for Crohn's Disease

Kaylie Chen, Johnson Chen, Emily Smith, Prerna Mathani, Randy Longman, Dana Lukin, Ellen Scherl, Juliette Gerber, Robert Battat

Summary: Higher concentrations of ustekinumab were found to be associated with improved radiologic and biomarker outcomes, validating previous studies using the same assay.

INFLAMMATORY BOWEL DISEASES (2022)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease

Hisashi Hirayama, Yasuhiro Morita, Takayuki Imai, Kenichiro Takahashi, Atsushi Yoshida, Shigeki Bamba, Osamu Inatomi, Akira Andoh

Summary: This study aimed to identify the optimal ustekinumab (UST) trough levels predicting clinical, laboratory, and endoscopic remission in Crohn's disease patients. The results showed that higher UST trough levels were required to achieve endoscopic remission compared to normalization of C-reactive protein and serum albumin levels.

BMC GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium

Amanda M. Johnson, Maria Barsky, Waseem Ahmed, Samantha Zullow, Jonathan Galati, Vipul Jairath, Neeraj Narula, Farhad Peerani, Benjamin H. Click, Elliot S. Coburn, ThucNhi Tran Dang, Stephanie Gold, Manasi Agrawal, Rajat Garg, Manik Aggarwal, Danah Mohammad, Brendan Halloran, Gursimran S. Kochhar, Hannah Todorowski, Nabeeha Mohy Ud Din, James Izanec, Amanda Teeple, Chris Gasink, Erik Muser, Zhijie Ding, Arun Swaminath, Komal Lakhani, Dan Hogan, Samit Datta, Ryan C. Ungaro, Brigid S. Boland, Matthew Bohm, Monika Fischer, Sashidhar Sagi, Anita Afzali, Thomas Ullman, Garrett Lawlor, Daniel C. Baumgart, Shannon Chang, David Hudesman, Dana Lukin, Ellen J. Scherl, Jean-Frederic Colombel, Bruce E. Sands, Corey A. Siegel, Miguel Regueiro, William J. Sandborn, David Bruining, Sunanda Kane, Edward V. Loftus, Parambir S. Dulai

Summary: This study evaluated the real-world effectiveness and safety of ustekinumab in patients with Crohn's disease. The results demonstrated that ustekinumab is a safe and effective treatment option for Crohn's disease, especially for biologic-naive patients.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn's Disease

Anna-Maria Globig, Nikola Patricia Sommer, Katharina Wild, Josefine Schardey, Katharina Zoldan, Anne Kerstin Thomann, Lucas-Alexander Schulte, Rupert Schreiner, Wolfgang Reindl, Jochen Klaus, Christoph Mathis Schempp, Maike Hofmann, Robert Thimme, Tobias Boettler, Peter Hasselblatt

Summary: TFH cells play a crucial role in the pathogenesis of CD, and Ustekinumab therapy affects TFH cell differentiation, thus influencing TFH-mediated immune functions in UST-treated CD patients.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Bridging Medical and Surgical Treatment of Inflammatory Bowel Disease: The Role of Interventional IBD

Bo Shen, Gursimran Kochhar, Tracy L. Hull, Udayakumar Navaneethan, Yan Chen, Xiuli Liu, David H. Bruining, Martin Lukas, Martin Bortlik, Darrell S. Pardi, Kaicun Wu, Shinji Okabayashi, Ajit Sood, David A. Schwartz, Francis A. Farraye

AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study

Johan Burisch, Konstantinos H. Katsanos, Dimitrios K. Christodoulou, Luisa Barros, Fernando Magro, Natalia Pedersen, Jens Kjeldsen, Zsuzsanna Vegh, Peter L. Lakatos, Carl Eriksson, Jonas Halfvarson, Mathurin Fumery, Corinne Gower-Rousseau, Marko Brinar, Silvija Cukovic-Cavka, Inna Nikulina, Elena Belousova, Sally Myers, Shaji Sebastian, Gediminas Kiudelis, Limas Kupcinskas, Doron Schwartz, Selwyn Odes, Ioannis P. Kaimakliotis, Daniela Valpiani, Renata D'Inca, Riina Salupere, Stefania Chetcuti Zammit, Pierre Ellul, Dana Duricova, Martin Bortlik, Adrian Goldis, Hendrika Adriana Linda Kievit, Alina Toca, Svetlana Turcan, Jongero Midjord, Kari Rubek Nielsen, Karina Winther Andersen, Vibeke Andersen, Ravi Misra, Naila Arebi, Pia Oksanen, Pekka Collin, Luisa de Castro, Vicent Hernandez, Ebbe Langholz, Pia Munkholm

JOURNAL OF CROHNS & COLITIS (2019)

Add to Collection

Article Gastroenterology & Hepatology

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study

Johan Burisch, Stefania Chetcuti Zammit, Pierre Ellul, Svetlana Turcan, Dana Duricova, Martin Bortlik, Karina Winther Andersen, Vibeke Andersen, Ioannis P. Kaimakliotis, Mathurin Fumery, Corinne Gower-Rousseau, Giulia Girardin, Daniela Valpiani, Adrian Goldis, Marko Brinar, Silvija Cukovic-Cavka, Pia Oksanen, Pekka Collin, Luisa Barros, Fernando Magro, Ravi Misra, Naila Arebi, Carl Eriksson, Jonas Halfvarson, Hendrika Adriana Linda Kievit, Natalia Pedersen, Jens Kjeldsen, Sally Myers, Shaji Sebastian, Konstantinos H. Katsanos, Dimitrios K. Christodoulou, Jongerd Midjord, Kari Rubek Nielsen, Gediminas Kiudelis, Limas Kupcinskas, Inna Nikulina, Elena Belousova, Doron Schwartz, Selwyn Odes, Riina Salupere, Amalia Carmona, Juan R. Pineda, Zsuzsanna Vegh, Peter L. Lakatos, Ebbe Langholz, Pia Munkholm

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

A novel porcine model of Crohn's disease anastomotic stricture

M. Lukas, M. Kolar, O. Ryska, S. Juhas, J. Juhasova, J. Kalvach, J. Pazin, J. Hadac, I. Vitkova, M. Bortlik, M. Lukas

JOURNAL OF CROHNS & COLITIS (2019)

Add to Collection

Article Gastroenterology & Hepatology

Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre

Martin Lukas, K. Malickova, M. Kolar, M. Bortlik, M. Vasatko, N. Machkova, V Hruba, D. Duricova, Milan Lukas

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Novel porcine model of Crohn's disease anastomotic stricture suitable for evaluation and training of advanced endoscopic techniques

Martin Lukas, Martin Kolar, Ondrej Ryska, Stefan Juhas, Jana Juhasova, Jaroslav Kalvach, Jaroslav Pazin, Tereza Kocisova, Ondrej Foltan, Hana Kristianova, Jan Ptacnik, Ivana Vitkova, Martin Bortlik, Milan Lukas

Summary: The study created a large animal model of anastomotic stricture with Crohn's disease properties, allowing for the development of new techniques and endoscopic interventions. The model demonstrated histologically verified changes similar to CD and maintained stable diameter for over 6 months, confirming the feasibility of endoscopic therapeutic interventions.

GASTROINTESTINAL ENDOSCOPY (2021)

Add to Collection

Article Cell Biology

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy

Dagmar Schierova, Radka Roubalova, Martin Kolar, Zuzana Stehlikova, Filip Rob, Zuzana Jackova, Stepan Coufal, Tomas Thon, Martin Mihula, Martin Modrak, Miloslav Kverka, Lukas Bajer, Klara Kostovcikova, Pavel Drastich, Jana Hercogova, Michaela Novakova, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska

Summary: This study investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and immune response in IBD patients. The results showed differences in microbiota diversity between healthy controls, Crohn's disease, and ulcerative colitis patients, with patients' microbiota becoming more similar to healthy controls after treatment. Additionally, increased IgM levels against specific gut commensals were observed after anti-TNF therapy.

CELLS (2021)

Add to Collection

Article Gastroenterology & Hepatology

A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts

M. Lukas, M. Kolar, J. Reissigova, D. Duricova, N. Machkova, V Hruba, M. Lukas, M. Vasatko, J. Jirsa, K. Pudilova, K. Malickova

Summary: This study compared the therapeutic effects of originator-adalimumab and SB5-adalimumab in patients with Crohn's disease. The results showed similar clinical disease activity, biological parameters, and pharmacokinetic profiles in both cohorts from week 52 to week 104. However, there was a lower treatment persistence rate for SB5-adalimumab due to local skin reaction events at the injection site.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study

Filip Rob, Dagmar Schierova, Zuzana Stehlikova, Jakub Kreisinger, Radka Roubalova, Stepan Coufal, Martin Mihula, Zuzana Jackova, Miloslav Kverka, Tomas Thon, Klara Kostovcikova, Lukas Bajer, Pavel Drastich, Jana Tresnak Hercogova, Michaela Novakova, Martin Kolar, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska

Summary: In this preliminary study, the longitudinal effect of ustekinumab on the immune system, skin and gut microbiota composition, and specific immune response to commensals was examined in patients with IBD. The findings provide valuable information for further understanding of the therapeutic effect and mechanism of ustekinumab.

PLOS ONE (2022)

Add to Collection

Article Immunology

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy

Zuzana Reiss, Filip Rob, Martin Kolar, Dagmar Schierova, Jakub Kreisinger, Zuzana Jackova, Radka Roubalova, Stepan Coufal, Martin Mihula, Tomas Thon, Lukas Bajer, Michaela Novakova, Martin Vasatko, Klara Kostovcikova, Natalie Galanova, Milan Lukas, Miloslav Kverka, Jana Tresnak Hercogova, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska

Summary: This study analyzed the temporal dynamics of skin microbiota and serum markers during anti-TNF therapy in IBD patients and found specific shifts in skin microbiota profile and a decrease in serum levels of L-FABP and I-FABP associated with anti-TNF-related skin adverse events.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2023)

Add to Collection

Article Immunology

Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD

Stepan Coufal, Miloslav Kverka, Jakub Kreisinger, Tomas Thon, Filip Rob, Martin Kolar, Zuzana Reiss, Dagmar Schierova, Klara Kostovcikova, Radka Roubalova, Lukas Bajer, Zuzana Jackova, Martin Mihula, Pavel Drastich, Jana Tresnak Hercogova, Michaela Novakova, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska

Summary: This study analyzed the serum biomarker dynamics in patients receiving anti-TNF-α therapy for inflammatory bowel disease (IBD). The levels of TGF-β1 and CD14 were found to be different between non-responders and responders, suggesting their potential as predictive markers for therapy failure.

JOURNAL OF IMMUNOLOGY RESEARCH (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project

K. Malickova, V. Pesinova, M. Bortlik, D. Duricova, N. Machkova, V. Hruba, M. Lukas, K. Mitrova, M. Vasatko, M. Kostrejova, M. Kolar, M. Lukas

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Review Gastroenterology & Hepatology

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases

Sang Hyoung Park, Jae Cheol Park, Milan Lukas, Martin Kolar, Edward V. Loftus

INTESTINAL RESEARCH (2020)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease

K. Pudilova, M. Kolar, D. Duricova, K. Malickova, V. Hruba, N. Machkova, R. Vanickova, K. Mitrova, M. Lukas, M. Vasatko, M. Lukas, M. Bortlik

JOURNAL OF CROHNS & COLITIS (2019)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.